Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the re-investment of dividends paid on January 8, 2009.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share purchase transactions:
- Ordinary shares were purchased at a price of £12.53 per share on January 15, 2009.
- Ordinary share ADRs were purchased at a price of $39.43 per ADR on January 12, 2009.
Material Changes
The filing details an increase in share interests for various executives following the dividend re-investment. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares and ADRs acquired by each listed executive to assess their current ownership stake.
- Confirm the dividend payment date of January 8, 2009, and the subsequent reinvestment execution dates (January 12 and 15, 2009).
- Note that this filing does not contain operational or financial performance data for the period.